India IPO SEBI DRHP Activity Filings — October 31, 2026

76.5% of IPO proceeds (₹307.50 Lakh of ₹402 Lakh) utilized with zero deviation, and full deployment in general corporate (₹19.55 Lakh) and issue expenses (₹45 Lakh) signals disciplined capital management

Machinery purchase (medical equipment) at 74.3% completion (₹194.95 Lakh of ₹262.45 Lakh) indicates ongoing capex for capacity expansion, a potential revenue driver for FY27

Revenue from operations at ₹407.87 Lakh for H1 FY27, down sharply from ₹600.87 Lakh in the prior full-year period, reflecting a significant business contraction

Net loss of ₹143.39 Lakh versus a profit of ₹30.31 Lakh a year earlier, a swing of ₹173.70 Lakh, indicating severe margin pressure and operational deterioration

EPS from continuing and discontinuing operations collapsed to ₹(4.02) from ₹5.21, a 177% decline, eroding shareholder value

Shareholders' funds declined 13.6% to ₹939.86 Lakh from ₹1,088.25 Lakh as reserves fell 20.5% to ₹576.23 Lakh from ₹724.62 Lakh, signaling balance-sheet weakening

IPO proceeds of ₹1,243 Lakh fully deployed (₹500 Lakh software, ₹500 Lakh working capital, ₹8.21 Lakh in escrow) yet financial performance worsened, suggesting poor capital efficiency

Medical tourism portal development only 64% complete (₹48 Lakh of ₹75 Lakh), leaving ₹27 Lakh unspent; delay could postpone digital revenue streams

No monitoring agency required for the issue, which is typical for SME IPOs but reduces external oversight on fund utilization

Board meeting on 31-Oct-2026 concluded in 30 minutes with no forward guidance or turnaround plan disclosed, leaving investors without visibility

Revenue contraction from ₹600.87 Lakh (prior full year) to ₹407.87 Lakh (H1 FY27) indicates a potential annualized run-rate of ~₹815 Lakh, still below prior year, raising going-concern concerns if losses persist

Net loss of ₹143.39 Lakh in H1 FY27 versus profit of ₹30.31 Lakh prior period, with no clear cost-cutting or revenue recovery plan disclosed

Reserves depleted by ₹148.39 Lakh (20.5% decline) to ₹576.23 Lakh, reducing buffer for future losses and potentially impairing net worth

Full deployment of ₹1,243 Lakh IPO proceeds into software and working capital has not translated into profitability, suggesting misallocation or weak demand

₹94.50 Lakh (23.5%) of IPO proceeds remain unutilized 26 months post-allotment, with medical tourism portal (₹27 Lakh unspent) and machinery (₹67.50 Lakh unspent) lagging, risking project delays

No monitoring agency appointed, reducing external scrutiny on remaining fund deployment

Basic and diluted EPS of ₹(4.02) versus ₹5.21 prior period, a 177% decline, which may trigger investor exit and liquidity pressure on the stock

Both filings show post-IPO disclosures with no insider buying or forward guidance, indicating low management conviction or limited communication, a common SME IPO governance gap

With 74% of machinery capex deployed, new medical equipment could drive revenue growth in H2 FY27; watch for utilization update in Q3 FY27 filing

Medical tourism portal, once completed (64% done), could tap into high-margin international patient flows, especially given India's cost-competitive healthcare positioning

Disciplined fund utilization and no deviation may attract ESG-conscious or governance-focused investors in the SME space

If the company can stabilize revenue at H1 FY27 levels and cut costs, the low base could set up for a turnaround; however, no guidance provided, so this is speculative

₹8.21 Lakh remaining in escrow is minimal, but full deployment means no further dilution risk from unutilized proceeds

Investors can screen for companies with high utilization rates and no deviation as a proxy for management quality, potentially avoiding value traps like Finelistings

Broach Lifecare utilized 76.5% of proceeds with no deviation, while Finelistings deployed 100% but saw financial deterioration, highlighting that utilization speed does not equate to value creation

Neither company appointed a monitoring agency (not mandatory for SME issues), and neither provided forward guidance or insider activity disclosures, limiting transparency for investors

Broach Lifecare's steady deployment contrasts with Finelistings' revenue decline and loss, underscoring the need for post-listing operational tracking beyond initial disclosures

Broach (healthcare) shows capex-led growth potential, while Finelistings (technology) faces revenue contraction, reflecting sector-specific challenges in SME tech

Monitor Q3 FY27 utilization statement for completion of medical tourism portal (₹27 Lakh remaining) and machinery (₹67.50 Lakh remaining); expected by Jan-2027

H2 FY27 results (due by Apr-2027) will be critical to see if losses widen or stabilize; no guidance provided, so any improvement would be a positive surprise

Watch for any board announcements on cost restructuring or capital raise, given declining reserves and net worth

Any announcement on medical tourism portal launch or new equipment commissioning could act as a catalyst

SEBI may consider mandatory monitoring agencies for SME IPOs above a certain size; watch for regulatory updates

Insider activity or shareholding pattern changes (next disclosure due Jan-2027) could signal management response to losses